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Summary Background Atezolizumab is an engineered im-
munoglobulin monoclonal antibody that targets the pro-
grammed death-1/programmed death-ligand 1 pathway.
Methods In this phase I dose-finding study, we assessed the
safety, feasibility, pharmacokinetics (PK), and exploratory
anti-tumor activity of atezolizumab monotherapy up to
20 mg/kg in Japanese patients with advanced solid tumors
who had failed standard therapy or for whom there is no stan-
dard therapy. Results Six patients were enrolled and received
intravenous atezolizumab every 3 weeks (q3w) at doses of 10
or 20 mg/kg. Tumor types were non-small cell lung cancer
(n = 3), melanoma (n = 1), pancreatic cancer (n = 1), and
thymic cancer (n = 1). No dose-limiting toxicities were ob-
served. All adverse events (AEs) were grade 1 or 2 in severity.
No discontinuations or deaths due to AEs were observed. As
of the data cutoff, no partial responses were observed; how-
ever, stable disease was observed in all six patients. The max-
imum mean serum atezolizumab concentration was 220 μg/
mL (SD ± 21.9), with 10-mg/kg dosing and 536 μg/mL
(SD ± 49.4) with 20-mg/kg dosing. Three patients were still
on treatment, and three of the six had achieved a progression-
free survival of >12 months. Conclusions Atezolizumab was
well tolerated in Japanese patients at doses up to 20 mg/kg
q3w. The safety profile and Cycle 1 serum atezolizumab con-
centrations were similar to those previously observed in non-
Japanese patients. These data support the participation of
Japanese patients in ongoing pivotal global studies of
atezolizumab.
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Introduction
Programmed death-ligand 1 (PD-L1) is an immune-
checkpoint protein within the cancer-immunity cycle that is
expressed on the surface of tumor cells (TC) and tumor-
infiltrating immune cells (IC) to downregulate T-cell function
[1]. PD-L1 binds to the programmed death-1 (PD-1) and B7.1
(CD80) proteins, and this binding can inhibit the killing of
tumor cells by the immune system and decrease T-cell activa-
tion, migration, and proliferation [1, 2]. Expression of PD-L1
is prevalent among many tumors, including lung cancer, ovar-
ian cancer, melanoma, brain tumors, malignant lymphoma,
multiple myeloma, and colon cancer, and its overexpression
is associated with poor prognosis in a number of cancers,
including renal cancer, melanoma, lung cancer, ovarian can-
cer, and colon cancer [3–8].
Atezolizumab (TECENTRIQ™, MPDL3280A, F.
Hoffmann-La Roche Ltd., Basel, Switzerland/Genentech,
Inc., South San Francisco, CA) is an engineered immunoglob-
ulin monoclonal anti-PD-L1 antibody. Inhibiting PD-L1 with
atezolizumab can restore the anti-tumor activity of T cells and
enhance T-cell priming [9–11]. Because atezolizumab does
not inhibit PD-L2/PD-1 interactions, immune homeostasis is
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presumably also maintained [11–15]. A previous phase Ia
study has shown that atezolizumab pharmacokinetics (PK)
are consistent with those of typical immunoglobulins, with a
mean terminal serum half-life of approximately 3 weeks [9].
Dose-limiting toxicities (DLTs) were not reported, neither was
a maximum tolerated dose, indicating that atezolizumab was
well tolerated up to 20 mg/kg every 3 weeks [9].
Atezolizumab’s clinical development began outside of Japan
in May 2011 for a number of cancers, including advanced or
recurrent non-small cell lung cancer and advanced or recurrent
renal cell carcinoma. Because atezolizumab may also benefit
Japanese patients, the objective of this study was to evaluate
the safety, feasibility, PK, and exploratory anti-tumor activity
of atezolizumab monotherapy up to 20 mg/kg in Japanese
patients with advanced solid tumors.
Patients and methods
Patient eligibility
Key inclusion criteria were as follows: Eastern Cooperative
Oncology Group Performance Status (ECOG PS) of 0 or 1,
age ≥ 20 years, solid tumor, life expectancy ≥12 weeks, ad-
vanced or recurrent cancer that was refractory to the standard
of care or for which no standard of care exists, measurable
disease, ability to provide a minimum of five unstained tumor
section slides prior to treatment (stored samples or samples col-
lected after enrollment), adequate bone marrow (white blood
cell count >2500/μL and <15,000/μL, absolute neutrophil count
≥1500/μL, lymphocyte count ≥500/μL, platelet count
≥10.0 × 104/μL), hemoglobin ≥9.0 g/dL, hepatic function (total
bilirubin ≤1.5 × the upper limit of normal [ULN], aspartate
aminotransferase and alanine aminotransferase ≤3.0 × ULN, al-
kaline phosphatase [ALP] ≤2.5 × ULN), renal function (serum
creatinine ≤1.5 × ULN), and coagulation (prothrombin time
international normalized ratio and activated partial thromboplas-
tin time ≤1.5 × ULN). The exclusion criteria were as follows:
history of anti-CTLA-4, PD-1, or PD-L1 antibody therapy, au-
toimmune disease, interstitial pneumonia or pulmonary fibrosis,
serious pre-existing medical condition (severe heart disease, un-
controlled diabetes, and active infection), hepatitis B or C virus
or human immunodeficiency virus infection, pericardial or pleu-
ral effusion requiring drainage, and primary central nervous sys-
tem tumors or symptomatic central nervous system metastases.
Study design and treatment
This was an open-label, multicenter, dose-escalation phase I
study (JO28944; JapicCTI-132208) conducted with two co-
horts (Cohort 1: atezolizumab 10 mg/kg every 3 weeks intra-
venously; Cohort 2: 20 mg/kg every 3 weeks intravenously).
Based on the results of the previously reported phase Ia US
study, the starting dose of atezolizumab was determined to be
10mg/kg [9]. Escalation to the higher-dose second cohort was
based on the occurrence of DLTs (see definitions below) dur-
ing the DLT evaluation period (21-day period from Day 1 of
Cycle 1), as follows (traditional 3 + 3 design): three patients
were entered at the initial dose level. If a DLTwas observed in
one-third of the patients at this dose level, an additional three
patients were entered at the same dose level. The dose level at
which at least two patients experienced DLTs was defined as
an unacceptable dose of atezolizumab in Japanese patients.
The primary objectives were identification of the AE and
DLT profiles and feasibility up to 20 mg/kg of atezolizumab.
The definition of DLT (i.e., unacceptable toxicity) was as fol-
lows: grade 4 neutropenia persisting ≥7 days or requiring treat-
ment with granulocyte colony-stimulating factor, febrile neutro-
penia, grade 4 thrombocytopenia or grade 3 decreased platelet
count requiring platelet transfusion, grade 4 anemia or grade 3
anemia requiring a red blood cell transfusion, and grade ≥ 3
nonhematologic toxicity, excluding controllable grade 3 nau-
sea, vomiting, or diarrhea that recovered to grade ≤ 1 as a result
of treatment prior to infusion in the next cycle. Secondary ob-
jectives reported here are PK and anti-tumor activity. PD-L1
expression is also shown (exploratory objective).
Assessments
AE severity was graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events v4.03. All AEs were assessed until 30 days after the
final infusion of atezolizumab. However, AEs were investi-
gated until the day before starting alternative treatment if the
patient was starting alternative treatment within 30 days after
the final infusion of atezolizumab, or until the day of the final
clinic visit if the patient was unable to visit the clinic (e.g., due
to hospital transfer or patient circumstances).
Tumor lesions were measured and evaluated in accordance
with Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1 [16]. Tumor lesions were assessed within 28 days
before enrollment, during the treatment period (Day 22 of
even-numbered cycles [−7 to +2 days; evaluation was to be
completed before infusion in the next cycle. If imaging
showed disease progression and the patient finished the study,
examination of lesions at completion of the study was not
mandatory]), and at the last observation.
Pharmacokinetics
Serum samples for PK analyses were collected at Cycle 1, Days
1 (before infusion, 30 ± 30 min after infusion), 2 (24 ± 6 h after
infusion), 4 (72 ± 12 h after infusion), 8 (± 1 day), 15 (± 1 day),
and 22 (± 1 day); Cycles 2, 3, and 4, Days 1 (30 ± 30 min after
infusion) and 22 (± 1 day); Cycles 5 and 7, Day 1 (30 ± 30 min
after infusion); and Cycle 6 onward, Day 22 of even-numbered
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cycles (± 1 day). The blood samples were centrifuged at 1500 to
2000×g for 15min at 4 °C. The serum samples were then stored
at −70 °C or less. The concentrations of atezolizumab in human
serum were measured using ELISA, with the lower limit of
quantification of 60 ng/mL.
The PK analysis included the maximum serum
atezolizumab concentration, the area under the serum concen-
tration–time curve from time zero to infinity, clearance (CL),
terminal elimination half-life (t1/2), volume of distribution at
steady state, and CV. These data were analyzed by the linear
log trapezoidal method with Phoenix WinNonlin version 6.2
(Pharsight Corporation, Mountain View, CA, USA).
PD-L1 expression level
PD-L1 expression was evaluated by the VENTANA SP142 an-
tibody (Ventana Medical Systems, Inc., Tucson, AZ). TC scores
were assigned based on the percentage of PD-L1-expressing TC
(TC3: ≥50 %; TC2: ≥5 % and <50 %; TC1: ≥1 % and <5 %;
TC0: <1 %). IC scores were assigned based on the percentage of
PD-L1-expressing IC within the tumor area (IC3: ≥10 %; IC2:
≥5 % and <10 %; IC1: ≥1 % and <5 %; IC0: <1 %).
Statistical analysis
The planned sample size was six to 12 patients, selected to
allow evaluation of the safety profile and tumor response and
to investigate PK and PD-L1 expression.
Results
Patients
Six patients were enrolled between September 2013 and
October 2013. The patients’ characteristics are listed in
Table 1. Three patients were men and three were women,
and their median age was 51 years (range, 41–69). Three
patients had non-small cell lung cancer (NSCLC; adenocarci-
noma), and one patient each had pancreatic cancer, melanoma,
or thymic cancer. The ECOGPSwas 0 in two patients and 1 in
four patients. No patients had TC3 or IC3 tumors. The patient
with thymic carcinoma had IC2 and TC2 scores, the patient
with pancreatic cancer had IC1 and TC0 scores, and the pa-
tient with melanoma had IC0 and TC0 scores. One of three
patients with NSCLC had IC1 and TC0 scores, another had
IC0 and TC0 scores, and the remaining patient’s NSCLC was
not assessable for IC or TC.
Three patients were enrolled in Cohort 1, and three were
enrolled in Cohort 2. The median duration of treatment was
53.9 weeks (range, 13.1–61.1) in Cohort 1 and 56.1 weeks
(12.1–56.9) in Cohort 2. Half of all patients were treated for
more than 1 year, and the patient with thymic cancer remained
on treatment as of December 2015 (more than 2 years of
treatment). The median relative dose intensity (actual
dose/planned dose × 100) was 94.7 % (range, 91.3 %–
98.1 %) in Cohort 1 and 98.80 % (96.2 %–100.3 %) in
Cohort 2.
Atezolizumab was started in all six enrolled patients,
and three of the six patients (one in Cohort 1 and two
in Cohort 2) were still participating in the study at the
time of data cutoff. Three patients withdrew due to in-
adequate responses.
Table 1 Patient characteristics
Characteristic No. of patients
Total no. of patients 6

















IC tumor-infiltrating immune cells, NA not assessable, NSCLC non-small
cell lung cancer, PD-L1 programmed death-ligand 1, TC tumor cells
Table 2 AEs in two or more patients
Atezolizumab dose 10 mg/kg 20 mg/kg Total
No. of patients n = 3 n = 3 n = 6
AE gradea 1 2 1 2 1 2
Rash 2 0 1 0 3 0
AST increased 1 0 1 0 2 0
ALT increased 1 0 1 0 2 0
ALP increased 0 1 1 0 1 1
Headache 2 0 0 0 2 0
AE adverse event, ALP alkaline phosphatase, ALT alanine aminotransfer-
ase, AST aspartate aminotransferase
a All AEs were grade 1 or 2
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Safety and tolerability
All six patients experienced AEs (24 individual events in
Cohort 1 and 18 in Cohort 2). One event (influenza-like
illness) was reported as serious. No events resulted in death
or discontinuation of study treatment, although three patients
experienced AEs that led to suspension of study treatment
(influenza-like illness and increased ALP in one patient each
in Cohort 1 and pneumonia in one patient in Cohort 2;
influenza-like illness and increased ALP were considered to
be related to atezolizumab). All events were grade 1 or 2.
Overall, rash was the most common related AE, followed by
increased aspartate aminotransferase, alanine aminotransfer-
ase, and ALP and headache (Table 2). No DLTs were reported;
therefore, the maximum tolerated dose was not reached.
Overall, no new safety signals were observed.
Pharmacokinetics
The PK evaluation was performed in all six patients.
The PK profile of atezolizumab is summarized in
Table 3, and the mean serum concentration–time pro-
fi les of atezolizumab are il lustrated in Fig. 1.
Mean ± SD trough levels of atezolizumab during
Cycle 1 in Cohorts 1 and 2 were 36.8 ± 1.35 and
113 ± 11.3 μg/mL, respectively. The trough values from
Cycle 3 to Cycle 18 were 84.6 to 179 μg/mL and 232
to 292 μg/mL, respectively. The doses for each patient
were 446, 469, and 713 mg in Cohort 1 and 1088,
1446, and 1626 mg in Cohort 2. CL and t1/2 were
similar in the two cohorts. The mean ± SD CL was
236 ± 57.2 mL/day in Cohort 1 and 213 ± 60.9 mL/
day in Cohort 2, and the t1/2 values were 11.7 ± 0.969
and 13.0 ± 1.32 days, respectively.
Tumor response
All six patients were evaluable for anti-tumor response with
RECIST version 1.1. The best overall response was stable
disease in all six patients (Table 4). Progression-free survival
was >12 months in three of six patients who remained on
treatment at data cutoff (Fig. 2).
Discussion
Atezolizumab is an engineered immunoglobulin 1 (IgG1)
monoclonal antibody that targets the PD-L1/PD-1 and PD-
L1/B7.1 (CD80) pathways. We conducted a phase I dose-
finding study of atezolizumab in Japanese patients with solid
tumors. Atezolizumab at 10 and 20 mg/kg every 3 weeks was
well tolerated in this Japanese patient population, since no
AEs met the definition of DLT. The safety profile was consis-
tent with that seen in a previous non-Japanese phase Ia clinical
study of atezolizumab [9].
The frequency of AEs is only a guide, because this was a
small study. Overall, the AE profile of atezolizumab in this
study was similar to that observed previously in the larger
phase Ia study in Western patients [9], and no new safety
concerns were identified. No AEs required medical treatment.
The most frequently reported AE was fatigue in previous non-
Japanese clinical studies of atezolizumab and of the anti-PD-1
antibodies nivolumab and pembrolizumab [9, 17–19]; howev-
er, no fatigue was observed in this study. The accumulation of
AE data in Japanese patients might be important in the future.
As with safety, serum atezolizumab concentrations in
Cycle 1 were similar to those seen in the previous non-
Japanese phase Ia clinical study of atezolizumab [9]. In con-
trast, the mean t1/2 was shorter in our study (<2 weeks
vs ≈ 3 weeks). In our study, the serum atezolizumab
Table 3 Pharmacokinetic
parameters of atezolizumab Parameter Unit n Mean SD CV (%) Geometric mean Geometric CV (%)
Cohort 1: 10 mg/kg
Cmax μg/mL 3 220 21.9 9.95 219 10.3
AUCinf day•μg/mL 3 2290 101 4.43 2290 4.49
CL mL/day 3 236 57.2 24.2 232 23.3
t1/2 day 3 11.7 0.969 8.31 11.6 8.51
Vss mL 3 3720 1140 30.6 3620 29.3
Cohort 2: 20 mg/kg
Cmax μg/mL 3 536 49.4 9.22 534 9.14
AUCinf day•μg/mL 3 6630 668 10.1 6610 10.4
CL mL/day 3 213 60.9 28.6 207 29.3
t1/2 day 3 13.0 1.32 10.1 13.0 10.2
Vss mL 3 3820 718 18.8 3780 18.8
AUCinf area under the serum concentration–time curve from time zero to infinity, CL clearance, Cmax maximum
serum concentration, t1/2 elimination half-life, Vss volume of distribution at steady state
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concentration (mean ± SD) was 36.8 ± 1.35 μg/mL or higher
when atezolizumab was administered at a dose of 10 mg/kg
every 3 weeks. The doses in each patient in the 10 mg/kg dose
group were 446, 469, and 713 mg, respectively, which were
lower than the 1200 mg dose being investigated in phase III
clinical studies of atezolizumab in solid tumors with study
sites in Japan (ClinicalTrials.gov; NCT02302807,
NCT02420821, NCT02367794, NCT02366143, and
NCT02409342). Therefore, the serum atezolizumab
concentration would also be 36.8 ± 1.35 μg/mL or higher if
the dose in each patient of our study was 1200 mg. The 1200
mg dose is expected to maintain a higher concentration than
10mg/kg, whichwas a sufficient dose in the phase Ia study [9]
and is lower than the 20 mg/kg dose in our study, which































































(A) Fig. 1 Mean ± SD serum
atezolizumab concentration–time
profile (semi-log scale) at first
infusion (a) and over 18 cycles
(b)
Table 4 Objective tumor
response and duration of
treatment
Dose level No. of cycles Primary tumor PD-L1 expression Best overall response
(mg/kg) IC score TC score
10 20 NSCLC NA NA SD
20 19 Thymic cancer 2 2 SD
20 18 NSCLC 0 0 SD
10 17 Pancreatic cancer 1 0 SD
10 4 NSCLC 1 0 SD
20 4 Melanoma 0 0 SD
IC tumor-infiltrating immune cells, NSCLC non-small cell lung cancer, PD-L1 programmed death-ligand 1, TC
tumor cells, NA not assessable
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showed no new safety signals. CL, determined from the serum
atezolizumab concentration at the first infusion using a
noncompartmental analysis, was similar in Cohorts 1 and 2.
CL did not tend to increase or decrease in a specific direction
when the dose was changed and was in the range of 156 to
302 mL/day. Therefore, CL does not change in the dose range
studied here (446–1626 mg; 10 or 20 mg/kg). Although our
study was limited in terms of the number of patients (N = 6),
systemic atezolizumab exposure is known to be unaffected by
differences in region or race [20].
The best overall response was stable disease in all
six pat ients, and progression-free survival was
>12 months in three patients. The response rate and
duration of response with atezolizumab were longer than
those in other Japanese phase I studies for patients after
standard therapy [21]. In a previous global phase Ia
study, there appeared to be an association between the
anti-tumor response with atezolizumab and the expres-
sion of PD-L1 in pretreatment samples. The association
of response to atezolizumab treatment and IC PD-L1
expression was statistically significant, whereas the as-
sociation with TC PD-L1 expression was not statistical-
ly significant across all tumor types in the phase Ia
study [9]. However, in our study, the level of PD-L1
expression and anti-tumor response did not follow any
specific pattern due to the small number of patients.
Evidence of anti-tumor response was limited in this
study; therefore, a relationship between the level of
PD-L1 expression and anti-tumor response could not
be determined in Japanese patients. The other explorato-
ry objectives were immunogenicity, T/B/NK cell counts,
and Fcγ receptor III polymorphism. We expected to
detect the utility of T/B/NK cell counts as a biomarker
and the relationship between AEs and Fcγ receptor III
polymorphism. However, no specific data were available
in this small study (data not shown). Additional
research is needed to identify adequate patients using
reliable biomarker to predict patient benefits.
In conclusion, the results of this study confirm that
atezolizumab is well tolerated in Japanese patients at a dosage
up to 20 mg/kg q3w. At this dose level, atezolizumab has an
acceptable toxicity profile with a PK profile similar to that
seen in a US phase I study. Overall, results obtained in this
study support the participation of Japanese patients in ongoing
pivotal global studies of atezolizumab in advanced solid tu-
mors (ClinicalTrials.gov; NCT02302807, NCT02420821,
NCT02367794, NCT02366143, and NCT02409342).
Acknowledgments This study was sponsored by Chugai
Pharmaceutical Co., Ltd. Writing support by Daniel Clyde, PhD, was
provided by Chugai Pharmaceutical Co., Ltd.
Compliance with ethical standards
Conflicts of interest Hidenori Mizugaki has nothing to disclose.
Noboru Yamamoto reports grants from Chugai, grants from Eli Lilly,
grants from Taiho, grants from Eisai, grants from Quintiles, grants from
Astellas, grants from BMS, grants from Novartis, grants from Daiichi-
Sankyo, grants from Pfizer, grants from Boehringer Ingelheim, grants
from Kyowa-Hakko Kirin, grants from Bayer, outside the submitted
work.
Haruyasu Murakami reports personal fees from Chugai, outside the
submitted work;
Hirotsugu Kenmotsu reports personal fees from Chugai
Pharmaceutical Co, Ltd., outside the submitted work.
Yutaka Fujiwara reports grants from AstraZeneca, grants from Eli
Lilly, grants from Eisai, grants from MerckSerono, grants from Chugai,
grants from GlaxoSmithKline, outside the submitted work.
Yoshimasa Ishida is a full time employee of Chugai Pharmaceutical.
Tomohisa Kawakami is a full time employee of Chugai
Pharmaceutical.
Toshiaki Takahashi reports grants and personal fees fromAstraZeneca
K.K., grants and personal fees from Eli Lilly Japan K.K., grants and
personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal
fees from Ono Pharmaceutical Co., Ltd., personal fees from Boehringer
Ingelheim Japan, INC, outside the submitted work.
PFS (months)















Fig. 2 Duration of progression-
free survival * Censored
observation. NSCLC non-small
cell lung cancer, PFS
progression-free survival
Invest New Drugs (2016) 34:596–603 601
Ethical approval Written informed consent was obtained from all pa-
tients. This study was approved by the institutional review board at the
National Cancer Center and Shizuoka Cancer Center and was conducted
in accordance with Japanese Good Clinical Practice (GCP) guidelines.
The study was conducted in compliance with the Declaration of
Helsinki, the study protocol, the standards stipulated in Paragraph 3 of
Article 14 and Article 80–2 of the Act on Securing Quality, Efficacy and
Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular
Therapy Products, Gene Therapy Products, and Cosmetics
(Pharmaceuticals and Medical Devices Act), and the Ministerial
Ordinance on Good Clinical Practice for Drugs (GCP).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Chen DS, Mellman I (2013) Oncology meets immunology: the
cancer-immunity cycle. Immunity 39:1–10. doi:10.1016/j.
immuni.2013.07.012
2. Zou W, Chen L (2008) Inhibitory B7-family molecules in the tu-
mour microenvironment. Nat Rev Immunol 8:467–477.
doi:10.1038/nri2326
3. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB,
Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L
(2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a po-
tential mechanism of immune evasion. Nat Med 8:793–800.
doi:10.1038/nm730
4. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM,
Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute
ML, Sebo TJ, Cheville JC, Kwon ED (2006) Tumor B7-H1 is
associated with poor prognosis in renal cell carcinoma patients with
long-term follow-up. Cancer Res 66:3381–3385. doi:10.1158
/0008-5472.CAN-05-4303
5. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T,
Okazaki T, Tokura Y (2010) Tumor cell expression of programmed
cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Cancer 116:1757–1766. doi:10.1002/cncr.24899
6. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG (2011) High
expression of PD-L1 in lung cancer may contribute to poor prog-
nosis and tumor cells immune escape through suppressing tumor
infiltrating dendritic cells maturation. Med Oncol 28:682–688.
doi:10.1007/s12032-010-9515-2
7. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y,
Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo
T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-
infiltrating CD8 + T lymphocytes are prognostic factors of human
ovarian cancer. Proc Natl Acad Sci U S A 104:3360–3365.
doi:10.1073/pnas.0611533104
8. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery
to clinical application. Int Immunol 19:813–824. doi:10.1093
/intimm/dxm057
9. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon
MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN,
Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y,
Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS
(2014) Predictive correlates of response to the anti-PD-L1 antibody
MPDL3280A in cancer patients. Nature 515:563–567. doi:10.1038
/nature14011
10. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt
J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS,
Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treat-
ment leads to clinical activity in metastatic bladder cancer. Nature
515:558–562. doi:10.1038/nature13904
11. Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-
generation immunotherapy–inhibiting programmed death-ligand 1
and programmed death-1. Clin Cancer Res 18:6580–6587.
doi:10.1158/1078-0432.CCR-12-1362
12. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman
GJ, Sharpe AH, Umetsu DT, Dekruyff RH (2010) PD-L1 and
PD-L2 modulate airway inflammation and iNKT-cell-
dependent airway hyperreactivity in opposing directions.
Mucosal Immunol 3:81–91. doi:10.1038/mi.2009.112
13. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O,
Wood CR, Greenfield EA, Freeman GJ (2003) Blockade of
programmed death-1 ligands on dendritic cells enhances T cell
activation and cytokine production. J Immunol 170:1257–
1266. doi:10.4049/jimmunol.170.3.1257
14. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M,
Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield
EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM,
Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe
AH, Freeman GJ (2001) PD-L2 is a second ligand for PD-1
and inhibits T cell activation. Nat Immunol 2:261–268.
doi:10.1038/85330
15. Matsumoto K, Fukuyama S, Eguchi-Tsuda M, Nakano T,
Matsumoto T, Matsumura M, Moriwaki A, Kan-o K, Wada
Y, Yagita H, Shin T, Pardoll DM, Patcharee R, Azuma M,
Nakanishi Y, Inoue H (2008) B7-DC induced by IL-13 works
as a feedback regulator in the effector phase of allergic asth-
ma. Biochem Biophys Res Commun 365:170–175.
doi:10.1016/j.bbrc.2007.10.156
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent
D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M,
Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D,
Verweij J (2009) New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J
Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026
17. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE,
Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado
E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel
L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L,
Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR
(2015) Nivolumab versus docetaxel in advanced squamous-
cell non-small-cell lung cancer. N Engl J Med 373:123–135.
doi:10.1056/NEJMoa1504627
18. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready
NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F,
Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H,
Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi
N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C,
Harbison CT, Graf Finckenstein F, Brahmer JR (2015)
Nivolumab versus docetaxel in advanced nonsquamous non-
small-cell lung cancer. N Engl J Med 373:1627–1639.
doi:10.1056/NEJMoa1507643
19. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han
JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler
MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, E I,
Dolled-Filhart M, Garon EB (2015) Pembrolizumab versus
docetaxel for previously treated, PD-L1-positive, advanced
non-small-cell lung cancer (KEYNOTE-010): a randomised
controlled trial. Lancet pii S0140-6736(15):01281–01287.
doi:10.1016/S0140-6736(15)01281-7
602 Invest New Drugs (2016) 34:596–603
20. US Food and Drug Administration (2016) TECENTRIQ™
(atezolizumab) injection for intravenous use. Initial US approval.
Highlights of prescribing information. http://www.accessdata.fda.
gov/drugsatfda_docs/label/2016/761034Orig1s000lbl.pdf.
Accessed 27 May 2016
21. Mizugaki H, Yamamoto N, Fujiwara Y, Nokihara H, Yamada Y,
Tamura T (2015) Current status of single-agent phase I trials in
Japan: towards globalization. J Clin Oncol 33:2051–2061.
doi:10.1200/JCO.2014.58.4953
Invest New Drugs (2016) 34:596–603 603
